OakChart

Metagenomi Therapeutics Inc

MGXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 11:15 AM ET

0.8199+0.1199 (17.13%)
2026-11-11 17:15 CET
Market cap
26.44 USD m
Revenue, TTM
7.09 USD m
Net income, TTM
-94.19 USD m
Free cash flow, TTM
-83.53 USD m
EPS diluted, TTM
-2.50
P/E
-
Compare

Price

MGX against its 20, 50 and 200-day averages
2050200beatmiss
1.001.50267K534KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MGXclose 0.8220-day 0.7950-day 0.97200-day 1.260.8252w low

63.2% under the 52-week high of 2.23 on 11 Nov 2025. 52-week low 0.60 on 6 Nov 2026. Last 15 sessions, 47.8% high to low

Profile

MGX
52-week range, 13% of the way up
0.602.23

Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Employees119
IPOFeb 09, 2024
Beta0.84
ATR, 14d0.08
Rel volume4.85
Short float4.46%
Insider own21.07%
Inst own16.26%

Snapshot

6 groups

Valuation

Index-
Market Cap30.97M
Enterprise Value-34.49M
Income-94.19M
Sales7.09M
Book/sh2.46
Cash/sh2.69
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees119
IPOFeb 09, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S4.37
P/B0.33
P/C0.30
P/FCF-
EV/EBITDA-
EV/Sales-4.86
Quick Ratio3.43
Current Ratio3.43
Debt/Eq0.39
LT Debt/Eq0.32
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.50
EPS next Y-1.84
EPS next Q-0.53
EPS this Y-2.67%
EPS next Y24.04%
EPS next 5Y7.79%
EPS past 3/5Y-26.57% -42.49%
Sales past 3/5Y13.59% 219.15%
EPS Y/Y TTM-5.97%
Sales Y/Y TTM-77.08%
EPS Q/Q-2.44%
Sales Q/Q-74.78%
EarningsNov 10 AMC
EPS/Sales Surpr.12.43% -15.18%

Ownership

Insider Own21.07%
Insider Trans0.11%
Inst Own16.26%
Inst Trans-1.57%
ROA-46.48%
ROE-69.35%
ROIC-76.56%
Gross Margin28.11%
Oper. Margin-1410.57%
Profit Margin-1329.31%
SMA204.38%
SMA50-15.56%
SMA200-34.75%
Trades-

Technical

Shs Outstand37.81M
Shs Float29.82M
Short Float4.46%
Short Ratio8.56
Short Interest1.33M
52W High2.23 -63.23%
52W Low0.60 36.65%
Volatility12.45% 10.19%
ATR (14)0.08
RSI (14)47.66
Beta0.84
Rel Volume4.85
Avg Volume155.25K
Volume230,290

Performance

Perf Week3.78%
Perf Month-10.62%
Perf Quarter-33.34%
Perf Half Y-40.59%
Perf YTD-49.39%
Perf Year-62.73%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.40
Target Price7.00
Prev Close0.70
Price0.82
Change %17.13%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Jul 07, 2026ResumedCChardan Capital MarketsBuy$5+509.8%
May 07, 2024InitiatedHH.C. WainwrightBuy$10+1,119.7%
May 02, 2024DowngradeJJP MorganOverweight → Neutral$16 → $6+631.8%
Mar 05, 2024InitiatedWWells FargoOverweight$25+2,949.2%
Mar 05, 2024InitiatedTTD CowenOutperform
Mar 05, 2024InitiatedJJP MorganOverweight$16+1,851.5%
Mar 05, 2024InitiatedJJefferiesBuy$23+2,705.2%
Mar 05, 2024InitiatedCChardan Capital MarketsBuy$21+2,461.3%
Mar 05, 2024InitiatedBBMO Capital MarketsOutperform$22+2,583.3%

Peers

Mkt cap
TickerCompanyMkt cap
CRBUCaribou Biosciences Inc40.53M
DTILPrecision Biosciences Inc255.61M
EDITEditas Medicine Inc375.82M
PRMEPrime Medicine Inc777.20M
NTLAIntellia Therapeutics Inc1.61B
BEAMBeam Therapeutics Inc2.63B
CRSPCRISPR Therapeutics AG4.40B
LXEOLexeo Therapeutics Inc257.35M
PASGPassage Bio Inc12.29M
TSHATaysha Gene Therapies Inc1.39B

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Reid LaurenceDirectorSep 09 '26Buy1.1720,00023,40120,000Sep 11 07:51 PM
Wein MatthewSee RemarksSep 08 '26Sale1.16358415126,133Sep 10 03:47 PM
Irish JianSee RemarksSep 08 '26Sale1.162,1402,479375,393Sep 10 03:40 PM
Wapnick PamelaChief Financial OfficerSep 08 '26Sale1.161,9112,214206,580Sep 10 03:34 PM
Wapnick PamelaChief Financial OfficerJun 05 '26Sale1.302,8843,746208,491Jun 10 11:23 AM
Irish JianSee RemarksJun 05 '26Sale1.303,7374,854377,533Jun 10 11:21 AM
Wein MatthewSee RemarksJun 05 '26Sale1.30558725126,491Jun 10 11:19 AM
Wapnick PamelaChief Financial OfficerMar 05 '26Sale1.601,5812,530187,375Mar 09 05:16 PM
Wein MatthewSee RemarksMar 05 '26Sale1.60482771114,549Mar 09 05:16 PM
Irish JianChief Executive OfficerMar 05 '26Sale1.601,6072,571333,770Mar 09 05:15 PM
Thomas Brian C.DirectorDec 05 '25Sale1.773,8306,7862,510,960Dec 08 01:56 PM
Wein MatthewSee RemarksDec 05 '25Sale1.77199353115,031Dec 08 01:51 PM
Wapnick PamelaChief Financial OfficerDec 05 '25Sale1.771,5762,793188,956Dec 08 01:49 PM
Irish JianChief Executive OfficerDec 05 '25Sale1.771,6022,839563,839Dec 08 01:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 98
  • Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London (GlobeNewswire) +17.13%
  • Metagenomi Therapeutics: Q3 Earnings Snapshot (Associated Press)
  • Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting (GlobeNewswire)
  • Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference (GlobeNewswire) -10.07%
  • Loading…
  • Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
  • Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Metagenomi Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results (GlobeNewswire)
  • Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
  • Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
  • Metagenomi Therapeutics: Q1 Earnings Snapshot (Associated Press)
  • Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.560-0.640-0.5592.182.585
2026Q22026-08-10-0.730-0.553-0.730-0.263.015
2026Q12026-05-11-0.610-0.553-0.6141.255.904
2025Q42026-03-05-0.590-0.606-0.5993.917.335
2025Q32025-11-11-0.550-0.585-0.5468.667.825
2025Q22025-08-12-0.540-0.619-0.5368.518.456
2025Q12025-05-13-0.680-0.609-0.6764.138.306
2024Q42025-03-17-0.370-0.749-0.6259.629.237
2024Q32024-11-13-0.510-0.776-0.51111.516.767
2024Q22024-08-14-0.290-0.653-0.28720.0112.656
2024Q12024-05-14-1.190-0.837-1.19011.167.867
2023Q42024-03-28-4.722-5.670-0.51512.4011.602
2026Q4---0.539--2.585
2027Q1---0.470--2.652
2027Q2---0.470--2.652
2027Q3---0.515--1.252

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-20.050-19.540-1.82244.7644.68
2024FY-2.360-2.479-2.08652.3051.81
2025FY-2.360-2.359-2.36025.2128.63
2026FY--2.433--5.36
2027FY--1.839--9.34
2028FY--1.822--6.69
2029FY--2.200--5.00
2030FY--1.990--15.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-114002.581.004.00
2026Q4S2026-11-104002.581.004.00
2026Q4S2026-10-254002.581.004.00
2026Q4S2026-08-204112.581.004.00
2026Q4S2026-08-115112.311.004.00
2026Q4S2026-07-265013.011.255.00
2026Q4S2026-07-135033.011.255.00
2026Q4S2026-07-064032.761.255.00
2026Q4S2026-05-124123.961.257.10
2026Q4S2026-03-134005.903.9110.00
2026Q4S2026-03-063006.574.7010.00
2026Q4S2025-11-141005.005.005.00
2026Q4S2025-11-122007.505.0010.00
2026Q4S2025-11-1110010.0010.0010.00

Estimate history

EPS, annual-0.572-1.163-1.822-2.086-2.359-2.5014
Period20212022202320242025TTM
EPS, quarterly-0.511-0.625-0.676-0.536-0.546-0.599-0.614-0.73-0.559
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.24317.244.75652.29525.217.09
Period20212022202320242025TTM
Sales, quarterly11.5149.6144.1278.5138.6593.9111.248-0.2572.184
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual37.47237.47237.47237.41837.62137.806
Period20212022202320242025MRQ
Shares, quarterly37.43337.41837.38237.53337.54737.62137.64737.77737.806
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue7.0925.2152.3044.7617.200.24
Cost of Goods Sold Incl. D&A5.095.325.414.211.730.39
Gross Profit1.9919.8946.8940.5515.47-0.14
Selling, General and Administrative Excl. Other101.94115.91135.79119.0460.1123.80
Research and Development80.8494.43109.1894.4043.1414.48
Other Operating Expense0.000.000.000.000.000.00
Operating Income-99.95-96.01-88.90-78.49-44.64-23.95
Interest Expense0.000.000.000.000.100.30
Unusual Expense0.001.299.19-2.87-0.09-2.76
Net Income Before Taxes-94.15-87.93-83.57-60.23-41.02-21.44
Income Taxes0.04-0.06-5.518.032.570.00
Consolidated Net Income-94.19-87.87-78.06-68.25-43.59-21.44
Net Income From Continuing Operations-94.19-87.87-78.06-68.25-43.59-21.44
Net Income-94.19-87.87-78.06-68.25-43.59-21.44
EPS (Recurring)-2.49-2.33-1.91-1.88-1.17-0.62
EPS (Basic, Before Extraordinaries)-2.50-2.36-2.09-1.82-1.16-0.57
EPS (Diluted)-2.50-2.36-2.09-1.82-1.16-0.57
EBITDA-94.86-90.70-83.49-74.28-42.91-23.56
Non-Operating Income (Expense)5.809.3814.5215.393.620.05
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense7.829.3612.805.471.550.38
Price To Sales Ratio-2.392.58---
Gross Margin28.1178.9189.6690.6089.92-59.26
Operating Margin-1,410.57-380.85-170.00-175.38-259.53-9,854.73
Net Margin-1,329.31-348.54-149.26-152.50-253.45-8,823.87
Shares Outstanding37.8137.6237.4237.4737.4737.47
Market Capitalization26.4426.44135.10131.73--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue2.18-0.261.253.918.668.514.139.61
Cost of Goods Sold Incl. D&A1.251.261.271.301.321.331.361.46
Gross Profit0.93-1.52-0.032.617.337.182.778.15
Selling, General and Administrative Excl. Other23.1627.2524.5626.9830.1728.1630.5928.78
Research and Development17.5322.5119.3021.5023.9621.1725.1423.16
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.23-28.77-24.59-24.37-22.84-20.99-27.82-20.62
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.001.290.007.13
Net Income Before Taxes-21.13-27.48-23.05-22.49-20.63-19.86-24.94-24.61
Income Taxes0.000.000.010.03-0.230.040.10-1.21
Consolidated Net Income-21.13-27.48-23.06-22.53-20.39-19.91-25.04-23.40
Net Income From Continuing Operations-21.13-27.48-23.06-22.53-20.39-19.91-25.04-23.40
Net Income-21.13-27.48-23.06-22.53-20.39-19.91-25.04-23.40
EPS (Recurring)-0.56-0.73-0.61-0.60-0.55-0.51-0.68-0.49
EPS (Basic, Before Extraordinaries)-0.56-0.73-0.61-0.60-0.55-0.54-0.68-0.63
EPS (Diluted)-0.56-0.73-0.61-0.60-0.55-0.54-0.68-0.63
EBITDA-20.97-27.51-23.31-23.07-21.52-19.65-26.46-19.16
Non-Operating Income (Expense)1.101.291.541.872.212.422.883.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.412.272.022.132.382.542.312.70
Price To Sales Ratio-3.302.262.422.861.631.112.58
Gross Margin42.58592.22-2.1666.7684.7184.3267.0984.80
Operating Margin-1,017.6711,195.72-1,970.11-623.04-263.76-246.53-674.10-214.51
Net Margin-967.3110,693.39-1,847.68-576.02-235.51-233.85-606.71-243.37
Shares Outstanding37.8137.7837.6537.6237.5537.5337.3837.42
Market Capitalization26.4444.8050.4160.8388.9555.3250.84135.10

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments160.80248.31271.18362.13108.15
Short Term Receivables1.502.862.451.660.19
Inventories0.000.000.000.000.00
Other Current Assets3.236.804.643.110.57
Total Current Assets165.54257.96278.27366.90108.92
Net Property, Plant & Equipment47.3857.6665.1533.2622.14
Total Investments and Advances7.358.7015.9213.8810.52
Deferred Tax Assets12.18----
Other Assets0.840.295.490.450.42
Total Assets233.28324.60364.84414.49141.99
Short Term Debt Incl. Current Port. of LT Debt6.035.593.431.510.69
Accounts Payable1.490.531.792.011.35
Income Tax Payable-0.003.271.540.00
Other Current Liabilities15.4231.1860.3843.4823.13
Total Current Liabilities22.9337.3168.8648.5425.17
Long Term Debt34.6340.1944.8017.0648.24
Provision for Risks Charges0.000.000.001.030.00
Deferred Tax Liabilities12.18----
Other Liabilities4.9412.2536.0176.1924.63
Total Liabilities74.6889.74149.67142.8198.04
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00350.76346.1076.50
Common Equity158.60234.86-135.58-74.43-32.54
Total Shareholders Equity158.60234.86215.17271.6843.95
Accumulated Minority Interest0.000.000.000.000.00
Total Equity158.60234.86215.17271.6843.95
Total Liabilities & Stockholders Equity233.28324.60364.84414.49141.99
Book Value Per Share4.226.28-3.62-1.99-0.87
Tangible Book Value Per Share4.226.28-3.62-1.99-0.87
Full-Time Employees119202236200-
Price to Book Ratio0.230.530.52--
Return on Assets-31.50-22.64-17.52-15.67-
Return on Equity-44.67-34.69-28.04-27.62-
Return on Invested Capital-45.47-28.38-26.25-15.10-23.26
Quick Ratio7.226.914.047.564.33
Current Ratio7.226.914.047.564.33

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-94.19-87.87-78.06-68.25-43.59-21.44
Depreciation5.095.325.414.211.730.39
Other Funds (Non Cash)14.5715.7523.25-0.932.10-0.94
Funds from Operations-74.53-66.80-49.41-64.98-39.76-22.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-8.79-22.09-59.67-26.4369.4946.26
Income Taxes Payable-0.00-3.271.731.540.00
Cash from Operating Activities-83.32-88.89-109.07-91.4129.7224.26
Capital Expenditures-0.21-0.57-3.11-9.81-13.98-2.90
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.040.000.000.000.00
Purchase or Sale of Investments85.90104.07-85.0455.55-108.22-71.41
Purchase of Investments-73.86-66.41-306.42-208.10-214.85-71.41
Sale Or Maturity of Investments159.76170.47221.38263.64106.630.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities85.68103.53-88.1645.73-122.20-74.32
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock0.170.2084.011.01239.599.95
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.170.2084.011.01239.599.95
Proceedsfrom Stock Options0.170.2084.011.01239.599.95
Issuance or Reduction of Debt, Net0.000.000.000.000.0029.97
Change in Long Term Debt0.000.000.000.000.0029.97
Issuance of Long Term Debt0.000.000.000.000.0029.97
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.05-0.560.000.000.000.00
Other Financing Activities Uses-0.05-0.560.000.000.000.00
Cash from Financing Activities0.11-0.3684.011.01239.5939.92
Net Change in Cash2.4814.28-113.22-44.66147.12-10.14
Free Cash Flow-83.53-89.47-112.19-101.2215.7521.35
Preferred Dividends (Cash Flow)-0.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments101.67120.66140.16160.80184.11204.99
Short Term Receivables0.600.901.001.502.262.27
Inventories0.000.000.000.000.000.00
Other Current Assets8.592.903.403.233.454.42
Total Current Assets110.86124.47144.56165.54189.82211.68
Net Property, Plant & Equipment38.9941.6744.9247.3849.9152.40
Total Investments and Advances6.556.556.557.357.407.40
Deferred Tax Assets---12.18--
Other Assets0.991.020.930.840.810.81
Total Assets157.39173.70196.95233.28247.94272.28
Short Term Debt Incl. Current Port. of LT Debt6.376.246.116.035.575.51
Accounts Payable0.772.602.401.491.222.89
Other Current Liabilities25.2018.7914.0015.4222.8024.87
Total Current Liabilities32.3427.6322.5022.9329.5833.27
Long Term Debt29.8431.4833.0834.6336.0937.48
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---12.18--
Other Liabilities2.022.023.594.943.815.71
Total Liabilities64.2061.1359.1774.6869.4976.45
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity93.19112.57137.78158.60178.45195.83
Total Shareholders Equity93.19112.57137.78158.60178.45195.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity93.19112.57137.78158.60178.45195.83
Total Liabilities & Stockholders Equity157.39173.70196.95233.28247.94272.28
Book Value Per Share2.462.983.664.224.755.22
Tangible Book Value Per Share2.462.983.664.224.755.22
Full-Time Employees107113-119-171
Price to Book Ratio0.230.330.320.340.450.26
Return on Assets-46.48-41.91-34.71-31.50-29.27-26.47
Return on Equity-69.35-60.61-49.02-44.67-40.87-37.45
Return on Invested Capital-17.17-19.08-13.50-11.66-9.51-8.53
Quick Ratio3.434.506.437.226.426.36
Current Ratio3.434.506.437.226.426.36

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-21.13-27.48-23.06-22.53-20.39-19.91
Depreciation1.251.261.271.301.321.33
Other Funds (Non Cash)3.054.063.533.933.455.26
Funds from Operations-16.82-22.16-18.26-17.30-15.62-13.32
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.272.64-2.92-6.25-5.64-7.93
Income Taxes Payable---0.000.00-
Cash from Operating Activities-19.08-19.51-21.18-23.55-21.25-21.25
Capital Expenditures0.02-0.12-0.03-0.09-0.07-0.13
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.04
Purchase or Sale of Investments16.1433.294.0132.4527.4419.16
Purchase of Investments-13.66-3.91-36.75-19.55-6.06-18.51
Sale Or Maturity of Investments29.8037.2040.7652.0033.5037.67
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities16.1633.173.9932.3727.3619.07
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.070.000.090.000.11
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.070.000.090.000.11
Proceedsfrom Stock Options0.000.070.000.090.000.11
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.01-0.03-0.02-0.19-0.28
Other Financing Activities Uses0.00-0.01-0.03-0.02-0.19-0.28
Cash from Financing Activities0.000.07-0.030.07-0.19-0.17
Net Change in Cash-2.9213.72-17.228.895.92-2.35
Free Cash Flow-19.06-19.64-21.20-23.63-21.33-21.38

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 52.30M 2025: 25.21M
United States2024: 52.30M 2025: 25.21M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.46%1.3M29.8M152.34K
2026-10-154.33%1.3M29.8M157.16K
2026-09-304.27%1.3M29.8M161.01K
2026-09-154.80%1.4M29.8M165.51K
2026-08-314.81%1.4M29.9M158.78K
2026-08-144.87%1.5M29.8M168.34K
2026-07-315.02%1.5M29.7M176.40K
2026-07-155.19%1.5M29.7M182.65K
2026-06-305.66%1.7M29.7M172.57K
2026-06-155.90%1.8M29.7M184.10K
2026-05-296.14%1.8M29.8M211.68K
2026-05-156.96%1.8M26.0M208.05K
2026-04-306.89%1.8M26.0M229.10K
2026-04-157.21%1.9M26.0M241.30K
2026-03-318.22%2.2M26.4M258.27K
2026-03-137.60%2.0M26.4M286.86K
2026-02-277.33%1.9M26.4M297.82K
2026-02-137.54%2.0M26.3M327.83K
2026-01-309.21%2.4M26.3M356.42K
2026-01-158.97%2.4M26.3M496.41K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-09-228-KCurrent report2026-09-21SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-10SCHEDULE 13GSEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC
2026-04-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-21SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-01SEC
2026-03-094Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-094Statement of changes in beneficial ownership of securities2026-03-05SEC
2026-03-094Statement of changes in beneficial ownership of securities2025-12-05SEC
2026-03-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0923.40K15.11K3
2026-080000
2026-070000
2026-06009.33K3
2026-050000
2026-040000
2026-03005.87K3
2026-020000
2026-010000
2025-120012.77K4
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.86%
RENAISSANCE TECHNOLOGIES LLC1.97%
Catalio Capital Management, LP1.41%
TWO SIGMA INVESTMENTS, LP1.36%
Peapod Lane Capital LLC1.30%
BRIDGEWAY CAPITAL MANAGEMENT, LLC1.06%
WELLS FARGO & COMPANY/MN1.01%
GEODE CAPITAL MANAGEMENT, LLC0.73%
PURA VIDA INVESTMENTS, LLC0.70%
BlackRock, Inc.0.68%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.97%
Old Westbury Small & Mid Cap Strategies Fund1.96%
Ultra-Small Company Fund0.87%
VANGUARD EXTENDED MARKET INDEX FUND0.84%
Avantis International Equity ETF0.51%
Fidelity Extended Market Index Fund0.36%
iShares Micro-Cap ETF0.25%
Ultra-Small Company Market Fund0.17%
Avantis International Small Cap Value Fund0.14%
Fidelity Total Market Index Fund0.12%

OakChart. MGX. Cached 15 minutes.